Comparing different surgical approaches for early-stage lung cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes the outcomes of robotic segmentectomies performed at four major medical centers, comparing them to video-assisted thoracoscopic surgery (VATS) and open surgical approaches. It aims to assess perioperative complications, surgery duration, lymph node dissection rates, and overall and disease-free survival across these techniques. The study includes patients diagnosed with non-small cell lung cancer (NSCLC) who underwent segmentectomies between January 2010 and December 2023. By evaluating these different surgical methods, the study seeks to provide insights into the most effective approaches for treating early-stage lung cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pre or post-operative diagnosis of NSCLC surgically treated with pulmonary segmentectomy from 1st January 2010 to the 31st to December 2023.
* Age \> then 18 years at the moment of surgery

Exclusion Criteria:

* Age \< then 18 years at the moment of surgery
* diagnosis other than NSCLC

Where it's running

• Istituto Clinico Humanitas
  Rozzano, Milan, Italy Recruiting
• Scientific Institute Ospedale San Raffaele
  Milan, Italy Recruiting
• Istituto Europeo di Oncologia
  Milan, Italy Recruiting
• Policlinico Universitario Agostino Gemelli
  Rome, Italy Recruiting

Study contacts

• Study coordinator: Pierluigi Novellis, Medical Doctor
• Email: novellis.pierluigi@hsr.it
• Phone: 0226437202

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.